Abstract:Gut microbiota is an indispensable commensal partner of human superorganism. The wealth of genetic repertoire provided by these microorganisms extends host's substrate processing capability. Energy and nutrient harvesting machinery primarily depends on the proper function of these organisms. However, the dynamic composition of microbiota changes with age, lifestyle, stress factors, infections, medications, and host pathophysiological conditions. Host immune system is primarily responsible for shaping up the microbial community and sustaining the symbiotic state. This involves controlling the delicate balance between agility toward pathobionts and tolerance toward symbionts. When things go wrong with this crosstalk, dysbiosis may arise.Metabolic syndrome is a multisystemic, low-grade chronic inflammatory disease that involves dyslipidemia, glucose intolerance, insulin resistance, and central obesity. Excess caloric intake with high-sugar and high-fat diet promote high energy harvesting and lipogenesis. The secretion of adipokines accompanies lipid spillover from fat cells, which contribute to insulin resistance and the expansion of adipose tissue in ectopic sites. Proinflammatory cytokines from adipose tissue macrophages increase the extent of adipose dysfunction.The inflammatory nature of obesity and metabolic syndrome recall the connection between dysbiosis and immune dysfunction. A remarkable association exits between obesity, inflammatory bowel disease, gluten-sensitive enteropathy, and dysbiosis. These conditions compromise the gut mucosa barrier and allow lipopolysaccharide to enter circulation. Unresolved chronic inflammation caused by one condition may overlap or trigger the other(s). Experimental studies and therapeutic trials of fecal microbiota transplantation promise limited improvement in some of these conditions.Typically, metabolic syndrome is considered as a consequence of overnutrition and the vicious cycle of lipogenesis, lipid accumulation, and chronic low-level inflammation. Because of the complex nature of this disorder, it remains inconclusive whether dysbiosis is a cause or consequence of obesity and metabolic syndrome.

Role of Metabolic Endotoxemia in Systemic Inflammation and Potential Interventions

Regulation of Gut Microbiota and Metabolic Endotoxemia with Dietary Factors

Involvement of gut microbiota in the development of low-grade inflammation and type 2 diabetes associated with obesity

Metabolic endotoxemia is dictated by the type of lipopolysaccharide

Lipopolysaccharides Derived from Gram-Negative Bacterial Pool of Human Gut Microbiota Promote Inflammation and Obesity Development

Changes in Gut Microbiota Control Metabolic Endotoxemia-Induced Inflammation in High-Fat Diet–Induced Obesity and Diabetes in Mice

Impaired Intestinal Barrier and Tissue Bacteria: Pathomechanisms for Metabolic Diseases

From the Gut to Neurodegeneration

Are gut dysbiosis, barrier disruption, and endotoxemia related to adipose tissue dysfunction in metabolic disorders? Overview of the mechanisms involved

Endotoxemia and Gastrointestinal Cancers: Insight into the Mechanisms Underlying a Dangerous Relationship

The Effect of Enteric-Derived Lipopolysaccharides on Obesity

Biomolecular Actions by Intestinal Endotoxemia in Metabolic Syndrome

Microbiota, inflammation and obesity

The relevance of intestinal barrier dysfunction, antimicrobial proteins and bacterial endotoxin in metabolic dysfunction‐associated steatotic liver disease

Microbiota and Lipotoxicity

Metabolic endotoxemia and cardiovascular disease: A systematic review about potential roles of prebiotics and probiotics

An Overview of Bioactive Compounds' Role in Modulating the Nrf2/Keap1/NF-κB Pathway to Alleviate Lipopolysaccharide-Induced Endometritis

The Role of Diet and Gut Microbiota in Regulating Gastrointestinal and Inflammatory Disease

The intestinal microbiota fuelling metabolic inflammation

Inflammation Meets Metabolic Disease: Gut Feeling Mediated by GLP-1

Metabolic Endotoxemia Initiates Obesity and Insulin Resistance